Zobrazeno 1 - 10
of 291
pro vyhledávání: '"Biagio, Ricciuti"'
Autor:
Marie-Julie Nokin, Alessia Mira, Enrico Patrucco, Biagio Ricciuti, Sophie Cousin, Isabelle Soubeyran, Sonia San José, Serena Peirone, Livia Caizzi, Sandra Vietti Michelina, Aurelien Bourdon, Xinan Wang, Daniel Alvarez-Villanueva, María Martínez-Iniesta, August Vidal, Telmo Rodrigues, Carmen García-Macías, Mark M. Awad, Ernest Nadal, Alberto Villanueva, Antoine Italiano, Matteo Cereda, David Santamaría, Chiara Ambrogio
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-18 (2024)
Abstract Selective KRASG12C inhibitors have been developed to covalently lock the oncogene in the inactive GDP-bound state. Two of these molecules, sotorasib and adagrasib, are approved for the treatment of adult patients with KRASG12C-mutated previo
Externí odkaz:
https://doaj.org/article/720b0c9c9a024f38961f97cf298e776d
Mechanistic patterns and clinical implications of oncogenic tyrosine kinase fusions in human cancers
Autor:
Taek-Chin Cheong, Ahram Jang, Qi Wang, Giulia C. Leonardi, Biagio Ricciuti, Joao V. Alessi, Alessandro Di Federico, Mark M. Awad, Maria K. Lehtinen, Marian H. Harris, Roberto Chiarle
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-19 (2024)
Abstract Tyrosine kinase (TK) fusions are frequently found in cancers, either as initiating events or as a mechanism of resistance to targeted therapy. Partner genes and exons in most TK fusions are followed typical recurrent patterns, but the underl
Externí odkaz:
https://doaj.org/article/f91a851ffb1747f5bdae9ea30cb198bb
Autor:
Biagio Ricciuti, MD, PhD, Arielle Elkrief, MD, Jessica Lin, MD, Jianjun Zhang, MD, Joao V. Alessi, MD, Giuseppe Lamberti, MD, PhD, Malini Gandhi, MD, Alessandro Di Federico, MD, Federica Pecci, MD, Xinan Wang, PhD, Maisam Makarem, MD, PhD, Cassio Murilo Hidalgo Filho, MD, Teresa Gorria, MD, Arushi Saini, BS, Cindy Pabon, MD, James Lindsay, PhD, Kathleen L. Pfaff, PhD, Emma L. Welsh, BS, Mizuki Nishino, MD, Lynette M. Sholl, MD, Scott Rodig, MD, Saadettin Kilickap, MD, Petra Rietschel, MD, Debra AG. McIntyre, PhD, Jean-Francois Pouliot, MD, Mehmet Altan, MD, Justin F. Gainor, MD, John V. Heymach, MD, Adam J. Schoenfeld, MD, Mark M. Awad, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 9, Pp 100675- (2024)
Introduction: Responses to first-line programmed cell death protein 1 inhibition vary among patients with metastatic NSCLC and a programmed death-ligand 1 (PD-L1) tumor proportion score (TPS) greater than or equal to 50%. We previously reported impro
Externí odkaz:
https://doaj.org/article/b469726a5a6d43d08be740aa9e8f7bc9
Autor:
Xinan Wang, Kangcheng Hou, Biagio Ricciuti, Joao V. Alessi, Xihao Li, Federica Pecci, Rounak Dey, Jia Luo, Mark M. Awad, Alexander Gusev, Xihong Lin, Bruce E. Johnson, David C. Christiani
Publikováno v:
HGG Advances, Vol 5, Iss 3, Pp 100320- (2024)
Summary: The KRAS mutation is the most common oncogenic driver in patients with non-small cell lung cancer (NSCLC). However, a detailed understanding of how self-reported race and/or ethnicity (SIRE), genetically inferred ancestry (GIA), and their in
Externí odkaz:
https://doaj.org/article/872f42da70b04727916e504d972d5581
Autor:
Joao V. Alessi, Biagio Ricciuti, Xinan Wang, Federica Pecci, Alessandro Di Federico, Giuseppe Lamberti, Arielle Elkrief, Scott J. Rodig, Emily S. Lebow, Jordan E. Eicholz, Maria Thor, Andreas Rimner, Adam J. Schoenfeld, Jamie E. Chaft, Bruce E. Johnson, Daniel R. Gomez, Mark M. Awad, Narek Shaverdian
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-12 (2023)
Abstract Although concurrent chemoradiation (CRT) and durvalumab consolidation has become a standard treatment for stage III non-small cell lung cancer (NSCLC), clinicopathologic and genomic factors associated with its efficacy remain poorly characte
Externí odkaz:
https://doaj.org/article/1cb0d71dba954b7a82afb042b77b3eda
Autor:
Mizuki Nishino, Biagio Ricciuti, Scott J Rodig, Joao V Alessi, Jia Luo, Mark M Awad, Bruce E Johnson, Federica Pecci, Alessandro Di Federico, Malini M Gandhi, Lynette M Sholl, Maisam Makarem, Emma Voligny, Tom Nguyen, Danielle Haradon
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/c9e8d5b05ce045b4979da2efc336b800
Autor:
Biagio Ricciuti, Joao V Alessi, Mark M Awad, Arielle Elkrief, Jamie E Chaft, Bruce E Johnson, Xinan Wang, Allison L Richards, Federica Pecci, Alessandro Di Federico, Adam J Schoenfeld, Malini M Gandhi, Adam Price, Emily S Lebow, Patricia Mae G Santos, Maria Thor, Andreas Rimner, Daniel R Gomez, Narek Shaverdian
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 11 (2023)
There is a need to identify predictive biomarkers to guide treatment strategies in stage III non-small cell lung cancer (NSCLCs). In this multi-institutional cohort of 197 patients with stage III NSCLC treated with concurrent chemoradiation (cCRT) an
Externí odkaz:
https://doaj.org/article/13b34cc4df014ca0bde4aed8a337931d
Autor:
Sara M Tolaney, James Lindsay, Michael Manos, Biagio Ricciuti, Anita Giobbie-Hurder, Scott J Rodig, Joao V Alessi, Mark M Awad, Sandro Santagata, Bruce E Johnson, Glenn J Hanna, Elio Adib, Jason Weirather, Xinan Wang, Bijaya Sharma, Kathleen Pfaff, Kristen D Felt, William Lotter, Panagiotis Konstantinopoulos, Madison Turner, Federica Pecci, Emma L Welsh, Stephanie M Jones, Jennifer O Altreuter, Ian D Dryg, Alessandro Di Federico, Malini M Gandhi, Sabrina J Chan, Marta Holovatska, Melissa E Hughes, O’Meara Tess A, Neal I Lindeman, Jennifer Curtis, Peter K Sorger, Ethan Cerami, Lynette M Sholl, Jonathan A Novak
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/02ccda4c59ce49c1ba7f9100a145659a
Publikováno v:
Drugs in Context, Vol 12, Pp 1-3 (2023)
This Editorial by De Giglio, Ricciuti and Metro introduces the series Treatment of advanced non-small-cell lung cancer: one size does not fit all: https://www.drugsincontext.com/special_issues/treatment-of-advanced-non-small-cell-lung-cancer-one-size
Externí odkaz:
https://doaj.org/article/dbfe31b6a9cd418ba52c81122f5bbcbd
Autor:
Biagio Ricciuti, Alessia Mira, Elisa Andrini, Pietro Scaparone, Sandra Vietti Michelina, Federica Pecci, Luca Cantini, Andrea De Giglio, Giuseppe Lamberti, Chiara Ambrogio, Giulio Metro
Publikováno v:
Drugs in Context, Vol 11, Pp 1-11 (2022)
Constitutive KRAS signalling drives tumorigenesis across several cancer types. In non-small-cell lung cancer (NSCLC) activating KRAS mutations occur in ~30% of cases, and the glycine to cysteine substitution at codon 12 (G12C) is the most common KRAS
Externí odkaz:
https://doaj.org/article/efd943eaa9a848c685b57be6b709cef3